Tissue microarrays: a current medical research tool

Shergill, Iqbal; Shergill, Navdeep Kooner; Arya, Manit; Patel, Hiten

doi:10.1185/030079904125003412

Cited by 61 publications

(52 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous reports reviewing the accuracy and reliability of tissue microarray vs standard sections on breast cancers have concluded that results derived from tissue microarrays are representative. 34,35 In this current study, when cases constructed in duplicate, triplicate and more microarray cores were compared, 85 and 92% of cases revealed agreement of p53 and CD117 immunohistochemical findings, respectively, when positive vs negative immunostaining of stromal cells was evaluated. We compared only stromal immunostaining as this was the cellular component under main scrutiny in these tumors.…”

Section: Discussionmentioning

confidence: 68%

p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study

et al. 2005

View full text Add to dashboard Cite

Breast phyllodes tumors are fibroepithelial neoplasms whose clinical behavior is difficult to predict on histology. There is relatively scant data on the role of biological markers. In this study, we determined if p53 and CD117 (c-kit) protein expression was predictive of behavior in a series of 335 phyllodes tumors diagnosed at the Singapore General Hospital, using immunohistochemistry on tissue microarrays. Representative areas from 250 (75%) benign, 54 (16%) borderline and 31 (9%) malignant phyllodes tumors were selected for construction of tissue microarrays using the 2 mm punch. Immunohistochemistry for p53 and CD117 was carried out using the streptavidin-biotin method. Staining proportion and intensity of both epithelial and stromal elements were analyzed. p53 immunostaining was observed in the epithelium of 28 (10%) of 278 microarrays; myoepithelium of 53 (21%) of 251 microarrays; and stromal cells in 105 (36%) of 289 microarrays. CD117 immunohistochemical reactivity was noted in epithelial and stromal components of 175 (of 267, 66%) and 17 (of 273, 6%) microarrays, respectively. Stromal p53 and CD117 protein expression was associated with tumor grade (Po0.05). Of 43 (13%) women who suffered recurrences during the follow-up period, CD117 stromal staining predicted recurrent disease (Po0.05), but p53 was not correlative. We conclude that tissue microarrays are a convenient method for evaluating immunostaining results of large numbers of phyllodes tumors. Although positive p53 stromal immunohistochemical detection may corroborate histologic malignancy, it is CD117 protein expression in phyllodes tumor stromal cells that may be of potential utility in predicting recurrent disease.

show abstract

Section: Discussionmentioning

confidence: 68%

p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…It allows rapid, high throughput expression profiling by IHC in archival tissues [19][20][21] and its utility has been validated by several studies using both epithelial and mesenchymal tumor samples. [22][23][24] More recently, tissue microarray has also been shown to be an effective method for the assessment of HER-2 gene amplification with fluorescent in situ hybridization or chromogenic in situ hybridization in breast tumors. 25,26 In searching for foundations for further investigation to optimize patient selection for cetuximab therapy, we sought to exploit both the chromogenic in situ hybridization and tissue microarray techniques, and to analyze the frequency of EGFR gene amplification and its relationship with immuno histochemical protein expression in colorectal carcinomas by performing a comparative immunohistochemical and chromogenic in situ hybridization study on tissue microarray sections.…”

mentioning

confidence: 99%

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

et al. 2005

View full text Add to dashboard Cite

Recent data suggest that detection of epidermal growth factor receptor protein by immunohistochemistry (IHC) does not predict response to the antiepidermal growth factor receptor drug, cetuximab, in patients with colorectal carcinoma. In searching for foundation for further investigation to optimize patient selection for cetuximab therapy, this study sought to exploit the tissue microarray and chromogenic in situ hybridization techniques to evaluate the status of epidermal growth factor receptor gene amplification in colorectal cancer and its relationship with protein expression by IHC. The study included 158 primary or metastatic colorectal adenocarcinomas. Immunohistochemical results were scored as 0-3 þ based on the intensity of membrane staining. The in situ hybridization signals were counted in 30 nuclei per tissue core. Overall, the rate of tissue loss was 7%, yielding 147 analyzable cases: 123 primary, 24 metastatic. Positive immunohistochemical staining of any intensity was detected in 85% (105/123) of primary and 79% (19/24) of metastatic tumors, whereas gene amplification (45 gene copies/nucleus) was only seen in 12% (15/123) of primary and 8% (2/24) of metastatic tumors. Only 2/15 primary and 1/2 metastatic tumors that showed gene amplification were amplified at a high level (410 gene copies/nucleus). Although a positive correlation was detected between the intensity of protein expression and the likelihood of gene amplification in both the primary (P ¼ 0.01) and the metastatic (P ¼ 0.05) tumors, IHC had a low specificity (17% in primary, 23% in metastatic) in predicting gene amplification. Conversely, all tumors that did not express the protein by IHC lacked gene amplification. Thus, this study shows that only a small fraction of epidermal growth factor receptor-positive colorectal carcinomas detected by IHC are associated with gene amplification. Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximabbased therapy. The epidermal growth factor receptor (EGFR) is a member of the HER tyrosine kinase growth factor receptor family, and is involved in signaling pathways affecting cell growth. [1][2][3][4] Recent studies have shown that EGFR expression is present in approximately 60-80% of colorectal carcinomas 5,6 and the receptor has emerged as a rational target for anticancer therapy in these tumors. 2,7 Cetuximab is a human-murine chimeric monoclonal antibody that specifically blocks the EGFR. Several clinical trials have demonstrated activity of cetuximab in patients with advanced colorectal carcinoma 3,4 and the drug is currently licensed in the US and Switzerland for use in such patients.

show abstract

“…Further confirmation is also highly recommended at the protein level, such as by Western blot analysis, flow cytometry or immunohistochemistry. In this context, it is currently possible to evaluate genes at the protein level using tissue microarray assays (31)(32)(33). Tissue microarray assay is a method that allows the evaluation of up to one thousand tissues at once using a specific marker.…”

Section: Analysis Tools For the Identification Of Gene Expression Patmentioning

confidence: 99%

A conceptual and practical overview of cDNA microarray technology: implications for basic and clinical sciences

Coelho

Hess

2005

Braz J Med Biol Res

View full text Add to dashboard Cite

AbstractcDNA microarray is an innovative technology that facilitates the analysis of the expression of thousands of genes simultaneously. The utilization of this methodology, which is rapidly evolving, requires a combination of expertise from the biological, mathematical and statistical sciences. In this review, we attempt to provide an overview of the principles of cDNA microarray technology, the practical concerns of the analytical processing of the data obtained, the correlation of this methodology with other data analysis methods such as immunohistochemistry in tissue microarrays, and the cDNA microarray application in distinct areas of the basic and clinical sciences.

show abstract

Tissue microarrays: a current medical research tool

Cited by 61 publications

References 25 publications

p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study

p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

A conceptual and practical overview of cDNA microarray technology: implications for basic and clinical sciences

Contact Info

Product

Resources

About